The world of biopharmaceuticals is a fast-paced and ever-evolving one, with investors keeping a close eye on the industry’s leading players for insights into potentially lucrative opportunities. Recently, CI Investments Inc. announced an impressive uptick in holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX), sowing excitement among investors who have long been watching the pharmaceutical giant from afar.
According to their most recent filing with the SEC, CI Investments Inc. increased its holdings in TG Therapeutics by a staggering 287.7% in the fourth quarter alone. The company had purchased an additional 6,760 shares during that period, bringing its holdings to a total of 9,110 shares at the end of the reporting period which were worth $108,000.
These developments have caught the attention and imagination of typical investors and analysts alike as they assess what this rise could mean for TG Therapeutics moving forward. These figures will also cement their interest in reviewing TP Therapeutics’ performance every quarter closely.
TG Therapeutics’ reputation as a biopharmaceutical firm was further validated when it posted quarterly earnings data on Monday, May 1st. The company took everyone by surprise by sharing better than expected earnings-per-share (EPS) for Q1/2021 despite having taken major losses recently; which should be considered as an added bonus for its stakeholders wherein ($0.36) was anticipated while TG’s EPS successively weighted up to ($0.28) per share!
Sell-side analysts are now forecasting that the American biopharma major is keen on leaving no stone unturned given its adverse return on equity of (213.67%) or negative net margin for Q1/2021 (i.e., net loss ratio alone stands at 1966.56%). The firm’s revenue clocked $7.80 million for Q1/2021 compared to $3.38 million in Q1/2020 (up 290% YoY basis). Such progress could be seen with a grain of salt, but it should provide analysts & investors with an optimistic outlook which is fortified by the fact that TG Therapeutics Inc. expects to land somewhere around the $-1 Earnings Per Share (EPS) for the fiscal year.
These exciting and buoyant developments have incited speculations among analysts who conjecture that TG Therapeutics might indeed be on the cusp of something rewarding that could create buzzes far & beyond. Investors are waiting with bated breath to see how this story continues to unfold and what prospects the future holds for TG Therapeutics. It might very well be a defining moment in biopharma history as it could keep people hopeful about biopharmaceutical breakthroughs!
Institutional Investors Boost Holdings in Biopharmaceutical Company TG Therapeutics, Inc.
TG Therapeutics, Inc., a biopharmaceutical company listed on the NASDAQ as TGTX, has recently seen changes in its stock holdings by several large investors. Institutional investors and hedge funds now own 68.06% of the company’s stock, according to sources.
Advisor Group Holdings Inc. raised its holdings in the company by 49.5% during the first quarter of this year and now owns 34,433 shares valued at $328,000 after acquiring an additional 11,406 shares last quarter. Raymond James & Associates also increased its holdings by 4.3%, while HighTower Advisors LLC raised its stake by 28.3%. MetLife Investment Management LLC made the most significant move among these investors with its holdings increasing by a massive 59%.
Finally, BlackRock Inc.’s holdings in TG Therapeutics were raised by 0.4% in the first quarter and now own an impressive 8,935,578 shares worth $84,978,000 after acquiring an additional 33,413 shares.
TGTX opened at $27.03 on Friday and remains highly sought-after with a market cap of $4.04 billion and a beta rating of 2.08. The stock’s PE ratio is -21.98 and has a fifty-day average price of $23.26 and a two-hundred day average price of $16.10.
The company maintains healthy debt-to-equity ratios and liquidity through quick ratios in addition to current ratios (of which the latter stands at nearly three). Given these solid finances amidst strong institutional investment interest and favorable technical factors such as moving averages for recent prices remaining high over past periods – it may make sense to keep your eye on TGTX for further growth opportunities down the line!
Discussion about this post